MAAL
Forumer attivo
infatti mi avevano dato come sicura la proposta a 39 e da verificare quella a 32.....
in compenso sulla 4k8 non avevano nessuna proposta
Obbligazioni perpetue e subordinate Tutto quello che avreste sempre voluto sapere sulle obbligazioni perpetue... - Cap. 1
- Creatore Discussione negusneg
- Data di Inizio
-
- Tags
- additional tier 1 bail in basilea 3 coco bonds crd iv genussscheine grandfathering hybrid bond loss absorption lower tier 2 make whole amount matusalem bond obbligazioni irredimibili obbligazioni perpetue obbligazioni subordinate perpetual bond preference shares restricted tier 1 tier 1 upper tier 2
- Stato
infatti mi avevano dato come sicura la proposta a 39 e da verificare quella a 32.....
in compenso sulla 4k8 non avevano nessuna proposta
bosmeld
Forumer storico
grazie dell'info
io ne volevo prendere giusto un cip, visto che ne ho già diverse dell'altra 4k8
alla fine non l'ho presa
e mi sono buttato su due titoli pazzerelli....
però strano che salgono tutti, e lei è l'unica che scende addirittura...
Imark
Forumer storico
I risultati del Q2/2009 di Bayer. In sintesi, material sciences (la chimica delle specialità, in sostanza) vede il proprio fatturato nel trimestre in calo del 30% su base annua; le altre divisioni sono in discreta crescita di fatturato su base annua (health care in particolare, con un +8,1%).
Complessivamente, le vendite declinano del 6%, l'utile netto del 7%.
The Associated Press July 29, 2009, 3:42AM ET
Germany's Bayer says Q2 profit down 7 pct
By MATT MOORE
BERLIN
German pharmaceutical and chemical company Bayer AG said Wednesday that its second-quarter profit slipped 7 percent as sagging sales for its plastics division offset better results from its health-care products.
The Leverkusen-based maker of Aspirin and the birth control pill Yasmin said net profit for the April-June period declined to euro532 million ($757 million) compared with euro574 million for the same quarter a year earlier.
Sales fell nearly 6 percent to euro8 billion compared with euro8.5 billion a year ago.
The company's materials science segment saw sales slide 30.2 percent to euro1.8 billion in the second quarter. The division supplies materials, coatings and adhesives to a wide range of customers: the auto industry, electronics, construction, sporting goods, packaging and medical equipment.
Though its overall sales were down, the company said it showed good growth at its health care unit, which makes Aspirin, Alka-Seltzer, Yasmin and the multiple sclerosis treatment Betaseron.
That helped push Bayer shares up 3.6 percent to euro41.50 in Frankfurt trading.
Looking ahead, the company said that while the global economy "remains in crisis" there are glimmers of hope.
"Expectations for the coming months have improved among both companies and consumers," Bayer said, adding it expects a moderate expansion of the pharmaceutical market, though growth in Europe and the U.S. -- key markets -- remained slow.
Bayer said second-quarter sales in its health care segment rose 8.1 percent to euro4 billion from euro3.7 billion a year earlier. Within the segment, the pharmaceutical business had an 8.3 percent increase in sales.
Consumer health care sales also gained, climbing nearly 7 percent to euro1.4 billion, Bayer said, with sales of products like aspirin showing signs of improvement as consumers began to spend more money.
Bayer's crop science division, whose products including pesticides, saw sales increase by 2 percent to euro1.8 billion.
Complessivamente, le vendite declinano del 6%, l'utile netto del 7%.
The Associated Press July 29, 2009, 3:42AM ET
Germany's Bayer says Q2 profit down 7 pct
By MATT MOORE
BERLIN
German pharmaceutical and chemical company Bayer AG said Wednesday that its second-quarter profit slipped 7 percent as sagging sales for its plastics division offset better results from its health-care products.
The Leverkusen-based maker of Aspirin and the birth control pill Yasmin said net profit for the April-June period declined to euro532 million ($757 million) compared with euro574 million for the same quarter a year earlier.
Sales fell nearly 6 percent to euro8 billion compared with euro8.5 billion a year ago.
The company's materials science segment saw sales slide 30.2 percent to euro1.8 billion in the second quarter. The division supplies materials, coatings and adhesives to a wide range of customers: the auto industry, electronics, construction, sporting goods, packaging and medical equipment.
Though its overall sales were down, the company said it showed good growth at its health care unit, which makes Aspirin, Alka-Seltzer, Yasmin and the multiple sclerosis treatment Betaseron.
That helped push Bayer shares up 3.6 percent to euro41.50 in Frankfurt trading.
Looking ahead, the company said that while the global economy "remains in crisis" there are glimmers of hope.
"Expectations for the coming months have improved among both companies and consumers," Bayer said, adding it expects a moderate expansion of the pharmaceutical market, though growth in Europe and the U.S. -- key markets -- remained slow.
Bayer said second-quarter sales in its health care segment rose 8.1 percent to euro4 billion from euro3.7 billion a year earlier. Within the segment, the pharmaceutical business had an 8.3 percent increase in sales.
Consumer health care sales also gained, climbing nearly 7 percent to euro1.4 billion, Bayer said, with sales of products like aspirin showing signs of improvement as consumers began to spend more money.
Bayer's crop science division, whose products including pesticides, saw sales increase by 2 percent to euro1.8 billion.
Imark
Forumer storico
Sul loro sito, una serie di dati fra i quali il calo di EBITDA ed EBIT e le cifre con riferimento a ciascuna singola divisione...
July 29, 2009
Interim report for the second quarter of 2009:
Bayer robust in a difficult environment
HealthCare strong – further growth at CropScience – MaterialScience stabilized / Group sales EUR 8,009 million (minus 5.9 percent) / EBITDA before special items EUR 1,765 million (minus 6.9 percent) / EBIT before special items EUR 1,101 million (minus 11.8 percent) / Group net income EUR 532 million (minus 7.3 percent) / Net cash flow EUR 1,399 million (plus 57.4 percent) /
Earnings targets for full year 2009 confirmed
.............
http://www.bayer.com/en/News-Detail.aspx?id=12171
July 29, 2009
Interim report for the second quarter of 2009:
Bayer robust in a difficult environment
HealthCare strong – further growth at CropScience – MaterialScience stabilized / Group sales EUR 8,009 million (minus 5.9 percent) / EBITDA before special items EUR 1,765 million (minus 6.9 percent) / EBIT before special items EUR 1,101 million (minus 11.8 percent) / Group net income EUR 532 million (minus 7.3 percent) / Net cash flow EUR 1,399 million (plus 57.4 percent) /
Earnings targets for full year 2009 confirmed
.............
http://www.bayer.com/en/News-Detail.aspx?id=12171
Ultima modifica:
BASCHENISSS
Nuovo forumer
GROSSO SALUTO A TUTTI: è la prima volta che scrivo,grazie per il prezioso lavoro che condividete,...... ho appena comprato bmps xs0121342827 da
iwbank prezzo 86,50. A risentirci
iwbank prezzo 86,50. A risentirci
Topgun1976
Guest
grazie dell'info
io ne volevo prendere giusto un cip, visto che ne ho già diverse dell'altra 4k8
alla fine non l'ho presa
e mi sono buttato su due titoli pazzerelli....
però strano che salgono tutti, e lei è l'unica che scende addirittura...
Qlc motivo cè,io stò seguendo un pò la situazione Austria Est Europa e non è per nulla Rosea,però può essere anche che sia indietro e parta a razzo.
X esempio La Lombarda e la Bpm sono a sconto rispetto ad altre.
Ps.Ho fatto l ' AAa47 venduto Lloyds a 60,ero troppo esposto
bosmeld
Forumer storico
Qlc motivo cè,io stò seguendo un pò la situazione Austria Est Europa e non è per nulla Rosea,però può essere anche che sia indietro e parta a razzo.
X esempio La Lombarda e la Bpm sono a sconto rispetto ad altre.
Ps.Ho fatto l ' AAa47 venduto Lloyds a 60,ero troppo esposto
ti straquoto, la lombarda è scontata, rispetto alle altre ubi, così come le bpm con le altre emissioni ita in genere.
hai liquidata tutta la llyods??? a me non sembra malaccio...
Topgun1976
Guest
Si avevo troppa esposizione e 20 emittenti diverse in Ptf,devo tagliarne qlc,sennò seguire tutto è impossibile.
La Lombarda dovrebbe avere almeno denaro 95,se consideri la call a Marzo 2010 e l ' interesse sopra l '8%,e invece a denaro a 85.
La Bpm interesse 8,4% addirittura denaro 82....
ferdo
Utente Senior
caspita corre pure questa: l'avevo presa a 56 venerdì scorso: 4 punti + gap denaro/lettera (erano un paio venerdì)Qlc motivo cè,io stò seguendo un pò la situazione Austria Est Europa e non è per nulla Rosea,però può essere anche che sia indietro e parta a razzo.
X esempio La Lombarda e la Bpm sono a sconto rispetto ad altre.
Ps.Ho fatto l ' AAa47 venduto Lloyds a 60,ero troppo esposto
Imark
Forumer storico
Con l'occasione riprendo un mio vecchissimo post del FOL che spiega la condizione di base del funzionamento di questo perpetual che paga il 5% fino al 2015 e dopo l' euribor a 3 mesi + il 2,8% (se non callato)
.....
Offering Circular pag 32... L'EBITDA come integrato da prospetto non deve essere inferiore al 7% del fatturato generato da vendite ... nel caso lo fosse, Bayer può scegliere se dare corso comunque al pagamento della cedola, posticipandolo, oppure annullarlo.
Nel 2006 i valori sono stati di 3.916 mln Eur a fronte di 28.956 mln Eur...
A “Cash Flow Event” shall exist if the Consolidated Gross Cash Flow (as defined below) of the Issuer is less than 7% of the Consolidated Sales Revenues (as defined below) of the Issuer, in each case as shown in
the the last published audited annual consolidated financial statements of the Issuer (drawn up in accordance with IFRS).
For these purposes, the “Consolidated Gross Cash Flow” shall be determined on the basis of the last published audited annual consolidated financial statements of the Issuer (drawn up in accordance with IFRS) by adjusting the consolidated operating result (EBIT) of the respective fiscal year (i) by adding the depreciation and amortisation, the loss on retirements of non-current assets and increase in pension provisions, and (ii) by deducting income taxes, gains on retirement of non-current assets and decrease in pension provisions.
In the event that during the life of the Bonds the Issuer is legally obliged to or makes use of a respective right to change the determination of Consolidated Gross Cash Flow in any of his financial statements or reportings, the aforementioned determination shall be applicable for the calculation of Consolidated Gross Cash Flow during the life of the Bonds.
For these purposes, the “Consolidated Sales Revenues” shall be the consolidated sales revenues as shown in the last published audited annual consolidated financial statements of the Issuer (drawn up in accordance with IFRS).
.....
Offering Circular pag 32... L'EBITDA come integrato da prospetto non deve essere inferiore al 7% del fatturato generato da vendite ... nel caso lo fosse, Bayer può scegliere se dare corso comunque al pagamento della cedola, posticipandolo, oppure annullarlo.
Nel 2006 i valori sono stati di 3.916 mln Eur a fronte di 28.956 mln Eur...
A “Cash Flow Event” shall exist if the Consolidated Gross Cash Flow (as defined below) of the Issuer is less than 7% of the Consolidated Sales Revenues (as defined below) of the Issuer, in each case as shown in
the the last published audited annual consolidated financial statements of the Issuer (drawn up in accordance with IFRS).
For these purposes, the “Consolidated Gross Cash Flow” shall be determined on the basis of the last published audited annual consolidated financial statements of the Issuer (drawn up in accordance with IFRS) by adjusting the consolidated operating result (EBIT) of the respective fiscal year (i) by adding the depreciation and amortisation, the loss on retirements of non-current assets and increase in pension provisions, and (ii) by deducting income taxes, gains on retirement of non-current assets and decrease in pension provisions.
In the event that during the life of the Bonds the Issuer is legally obliged to or makes use of a respective right to change the determination of Consolidated Gross Cash Flow in any of his financial statements or reportings, the aforementioned determination shall be applicable for the calculation of Consolidated Gross Cash Flow during the life of the Bonds.
For these purposes, the “Consolidated Sales Revenues” shall be the consolidated sales revenues as shown in the last published audited annual consolidated financial statements of the Issuer (drawn up in accordance with IFRS).
- Stato
Similar threads
- Bloccata
